Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Public University of Navarre, IdiSNA, 31008 Pamplona, Spain.
Department of Medical Oncology, Complejo Hospitalario de Navarra-IdiSNA, 31008 Pamplona, Spain.
Int J Mol Sci. 2021 Apr 3;22(7):3736. doi: 10.3390/ijms22073736.
Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of "hyperprogressive disease", and several definitions have been proposed for its identification, most of them relying on radiological criteria. However, due to the fact that the cellular and molecular mechanisms have not been elucidated yet, there is still some debate regarding whether this fast progression is induced by immunotherapy or only reflects the natural course of some highly aggressive neoplasms. Moreover, contradictory results of trials including patients with different cancer types suggest that both the incidence, the associated factors and the implications regarding prognosis might differ depending on tumor histology. This article intends to review the main publications regarding this matter and critically approach the most controversial aspects.
随着免疫疗法被定位为治疗多种肿瘤的首选方法,一种新的反应模式,即肿瘤生长的突然加速,已经被描述出来。这种现象被称为“超进展性疾病”,已经提出了几种用于识别它的定义,其中大多数依赖于影像学标准。然而,由于细胞和分子机制尚未阐明,关于这种快速进展是由免疫疗法引起的,还是仅仅反映了某些高度侵袭性肿瘤的自然病程,仍存在一些争议。此外,包括不同癌症类型患者的临床试验的结果相互矛盾,这表明发病率、相关因素以及对预后的影响可能因肿瘤组织学而异。本文旨在回顾这方面的主要出版物,并批判性地探讨最具争议的方面。